Neuroendocrine cancer vaccines in clinical trials

Expert Review of Vaccines

Volumn 10, Issue 6, 2011, Pages 811-823

  Bridle, Byram W ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

cancer vaccine; clinical trial; neuroblastoma; neuroendocrine tumor; prime boost; small cell lung carcinoma

Indexed keywords

ALPHA INTERFERON; ANTIBODY; ANTIIDIOTYPIC ANTIBODY; ANTINEOPLASTIC AGENT; BACTERIAL VACCINE; BCG VACCINE; CA 19-9 ANTIGEN; CALCITONIN; CANCER VACCINE; CD56 ANTIGEN; CHROMOGRANIN A; DENDRITIC CELL VACCINE; GANGLIOSIDE GD2; GANGLIOSIDE GD3; GANGLIOSIDE GD3L; GANGLIOSIDE GM2; GANGLIOSIDE GM2L; GLYCOSPHINGOLIPID; IMMUNOLOGICAL ADJUVANT; MELANOMA ANTIGEN 1; N GLYCOLYLGANGLIOSIDE GD3; NY ESO 1 ANTIGEN; PEPTIDE VACCINE; PROTEIN P53; RECOMBINANT INTERLEUKIN 7; SYNAPTOPHYSIN; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ADOPTIVE TRANSFER; ANTIBODY RESPONSE; ANUS CANCER; CANCER IMMUNIZATION; CANCER SURVIVAL; CARCINOID; CELL LYSATE; CLINICAL TRIAL (TOPIC); HUMAN; LUNG SMALL CELL CANCER; MERKEL CELL TUMOR; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; PANCREAS ISLET CELL TUMOR; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE; THYROID MEDULLARY CARCINOMA; TUMOR CELL; UTERINE CERVIX CANCER; VACCINATION;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; NEUROBLASTOMA; NEUROENDOCRINE TUMORS; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME; VACCINATION;

EID: 79959571198     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.68     Document Type: Review

References (123)

1. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 39(6), 707-712 (2010
2. Fujita T, Kobayashi S, Yui R. Paraneuron concept and its current implications. Adv. Biochem. Psychopharmacol. 25, 321-325 (1980
3. Le Douarin NM. On the origin of pancreatic endocrine cells. Cell 53(2), 169-171 (1988
4. Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumours. Endocr. Relat. Cancer 11(1), 1-18 (2004 (Pubitemid 38419720)
5. Yon L, Guillemot J, Montero-Hadjadje M et al. Identification of the secretogranin II-derived peptide EM66 in pheochromocytomas as a potential marker for discriminating benign versus malignant tumors. J. Clin. Endocrinol. Metab. 88(6), 2579-2585 (2003 (Pubitemid 36724427)
6. Guillemot J, Anouar Y, Montero-Hadjadje M et al. Circulating EM66 is a highly sensitive marker for the diagnosis and follow-up of pheochromocytoma. Int. J. Cancer 118(8), 2003-2012 (2006
7. Kanehira K, Khoury T. Neuroendocrine markers expression in pancreatic serous cystadenoma. Appl. Immunohistochem. Mol. Morphol. 19(2), 141-146 (2011
8. Farinola MA, Weir EG, Ali SZ. CD56 expression of neuroendocrine neoplasms on immunophenotyping by flow cytometry: a novel diagnostic approach to fine-needle aspiration biopsy. Cancer 99(4), 240-246 (2003 (Pubitemid 37012916)
9. Bahrami A, Gown AM, Baird GS, Hicks MJ, Folpe AL. Aberrant expression of epithelial and neuroendocrine markers in alveolar rhabdomyosarcoma: a potentially serious diagnostic pitfall. Mod. Pathol. 21(7), 795-806 (2008 (Pubitemid 351896668)
10. Bonkhoff H. Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. Ann. Oncol. 12(Suppl. 2), S141-S144 (2001 (Pubitemid 33069704)
11. Slominski A. Neuroendocrine activity of the melanocyte. Exp. Dermatol. 18(9), 760-763 (2009
12. Slominski A, Wortsman J, Luger T, Paus R, Solomon S. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol. Rev. 80(3), 979-1020 (2000 (Pubitemid 30452009)
13. Slominski A, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol. Rev. 84(4), 1155-1228 (2004 (Pubitemid 39287950)
14. Slominski A, Wortsman J, Tobin DJ. The cutaneous serotoninergic/ melatoninergic system: securing a place under the sun. FASEB J. 19(2), 176-194 (2005 (Pubitemid 40189259)
15. Eyden B, Pandit D, Banerjee SS. Malignant melanoma with neuroendocrine differentiation: clinical, histological, immunohistochemical and ultrastructural features of three cases. Histopathology 47(4), 402-409 (2005 (Pubitemid 41428489)
16. Navalkele P, O'Dorisio MS, O'Dorisio TM, Zamba GK, Lynch CF. Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975-2006. Pediatr. Blood Cancer 56(1), 50-57 (2011
17. Modlin IM, Oberg K, Chung DC et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 9(1), 61-72 (2008
18. Dworakowska D, Grossman AB. Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review. Endocr. Relat. Cancer 16(1), 45-58 (2009
19. Duerr EM, Chung DC. Molecular genetics of neuroendocrine tumors. Best Pract. Res. Clin. Endocrinol. Metab. 21(1), 1-14 (2007 (Pubitemid 46436730)
20. Almeida MQ, Stratakis CA. Solid tumors associated with multiple endocrine neoplasias. Cancer Genet. Cytogenet. 203(1), 30-36 (2010
21. Garland SM, Smith JS. Human papillomavirus vaccines: current status and future prospects. Drugs 70(9), 1079-1098 (2010
22. Wirnsberger G, Hinterberger M, Klein L. Regulatory T-cell differentiation versus clonal deletion of autoreactive thymocytes. Immunol. Cell Biol. 89(1), 45-53 (2011
23. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 100(11), 2014-2021 (2009
24. Coggin JH Jr, Barsoum AL, Rohrer JW, Thurnher M, Zeis M. Contemporary definitions of tumor specific antigens, immunogens and markers as related to the adaptive responses of the cancer-bearing host. Anticancer Res. 25(3c), 2345-2355 (2005 (Pubitemid 41044716)
25. Morran MP, Casu A, Arena VC et al. Humoral autoimmunity against the extracellular domain of the neuroendocrine autoantigen IA-2 heightens the risk of Type 1 diabetes. Endocrinology 151(6), 2528-2537 (2010
26. Ray S, Chhabra A, Mehrotra S et al. Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma. Clin. Dermatol. 27(6), 603-613 (2009
27. Hofman FM, Stathopoulos A, Kruse CA, Chen TC, Schijns VE. Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells. Anticancer Agents Med. Chem. 10(6), 462-470 (2010
28. Luo W, Hsu JC, Kieber-Emmons T, Wang X, Ferrone S. Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases. Cancer Chemother. Biol. Response Modif. 22, 769-787 (2005
29. Liu MA. Immunologic basis of vaccine vectors. Immunity 33(4), 504-515 (2010
30. Shurin MR, Gregory M, Morris JC, Malyguine AM. Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow? Expert Opin. Biol. Ther. 10(11), 1539-1553 (2010
31. Maris JM. Recent advances in neuroblastoma. N. Engl. J. Med. 362(23), 2202-2211 (2010
32. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 369(9579), 2106-2120 (2007 (Pubitemid 46935947)
33. Jacobs JF, Coulie PG, Figdor CG, Adema GJ, De Vries IJ, Hoogerbrugge PM. Targets for active immunotherapy against pediatric solid tumors. Cancer Immunol. Immunother. 58(6), 831-841 (2009
34. Modak S, Cheung NK. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest. 25(1), 67-77 (2007 (Pubitemid 46423592)
35. Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv. Exp. Med. Biol. 491, 369-402 (2001 (Pubitemid 32595136)
36. Cheung NK, Kushner BH, Cheung IY et al. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J. Clin. Oncol. 16(9), 3053-3060 (1998 (Pubitemid 28417426)
37. Cheung NK, Saarinen UM, Neely JE, Landmeier B, Donovan D, Coccia PF. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res. 45(6), 2642-2649 (1985 (Pubitemid 15024436)
38. Simon T, Hero B, Faldum A et al. Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy. Klin. Padiatr. 217(3), 147-152 (2005 (Pubitemid 40705235)
39. Simon T, Hero B, Faldum A et al. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J. Clin. Oncol. 22(17), 3549-3557 (2004 (Pubitemid 41103661)
40. Yu AL, Gilman AL, Ozkaynak MF et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 363(14), 1324-1334 (2010
41. Morgan RA, Dudley ME, Rosenberg SA. Adoptive cell therapy: genetic modification to redirect effector cell specificity. Cancer J. 16(4), 336-341 (2010
42. Savai R, Schermuly RT, Pullamsetti SS et al. A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cells. Cancer Res. 67(11), 5443-5453 (2007 (Pubitemid 46997285)
43. Raffaghello L, Prigione I, Airoldi I et al. Mechanisms of immune evasion of human neuroblastoma. Cancer Lett. 228(1-2), 155-161 (2005 (Pubitemid 41188437)
44. Cartellieri M, Bachmann M, Feldmann A et al. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J. Biomed. Biotechnol. 2010, 956304 (2010
45. Navid F, Santana VM, Barfield RC. Anti-GD2 antibody therapy for GD2- expressing tumors. Curr. Cancer Drug Targets 10(2), 200-209 (2010
46. Leen AM, Myers GD, Sili U et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat. Med. 12(10), 1160-1166 (2006 (Pubitemid 44527351)
47. Pule MA, Savoldo B, Myers GD et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14(11), 1264-1270 (2008
48. Geiger JD, Hutchinson RJ, Hohenkirk LF et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 61(23), 8513-8519 (2001 (Pubitemid 33131133)
49. Caruso DA, Orme LM, Neale AM et al. Results of a Phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro. Oncol. 6(3), 236-246 (2004 (Pubitemid 39136507)
50. Caruso DA, Orme LM, Amor GM et al. Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma. Cancer 103(6), 1280-1291 (2005 (Pubitemid 40328101)
51. Russell HV, Strother D, Mei Z et al. A Phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma. J. Immunother. 31(9), 812-819 (2008
52. Russell HV, Strother D, Mei Z et al. Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J. Immunother. 30(2), 227-233 (2007 (Pubitemid 46667802)
53. Bowman LC, Grossmann M, Rill D et al. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum. Gene Ther. 9(9), 1303-1311 (1998 (Pubitemid 28312895)
54. Bowman L, Grossmann M, Rill D et al. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood 92(6), 1941-1949 (1998
55. Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston PO. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int. J. Cancer 85(5), 659-666 (2000 (Pubitemid 30080479)
56. Ragupathi G, Livingston PO, Hood C et al. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin. Cancer Res. 9(14), 5214-5220 (2003 (Pubitemid 37413571)
57. Chapman PB, Morrissey DM, Panageas KS et al. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study. Clin. Cancer Res. 6(3), 874-879 (2000 (Pubitemid 30159343)
58. Ahlman H. Malignant pheochromocytoma: state of the field with future projections. Ann. NY Acad. Sci. 1073, 449-464 (2006 (Pubitemid 44912040)
59. Chong S, Lee KS, Chung MJ, Han J, Kwon OJ, Kim TS. Neuroendocrine tumors of the lung: clinical, pathologic, and imaging findings. Radiographics 26(1), 41-57; discussion 57-48 (2006
60. Toh CK, Gao F, Lim WT et al. Differences between small-cell lung cancer and non-small-cell lung cancer among tobacco smokers. Lung Cancer 56(2), 161-166 (2007 (Pubitemid 46590492)
61. Zereu M, Vinholes JJ, Zettler CG. p53 and Bcl-2 protein expression and its relationship with prognosis in small-cell lung cancer. Clin. Lung Cancer 4(5), 298-302 (2003 (Pubitemid 36546415)
62. Chiappori AA, Soliman H, Janssen WE, Antonia SJ, Gabrilovich DI. INGN-225: a dendritic cell-based p53 vaccine (Ad. p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin. Biol. Ther. 10(6), 983-991 (2010
63. Antonia SJ, Mirza N, Fricke I et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin. Cancer Res. 12(3 Pt 1), 878-887 (2006 (Pubitemid 43259871)
64. Jones PC, Sze LL, Liu PY, Morton DL, Irie RF. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J. Natl Cancer Inst. 66(2), 249-254 (1981 (Pubitemid 11117626)
65. Livingston PO, Wong GY, Adluri S et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. 12(5), 1036-1044 (1994 (Pubitemid 24145334)
66. Neninger E, Diaz RM, De La Torre A et al. Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a Phase I trial. Cancer Biol. Ther. 6(2), 145-150 (2007 (Pubitemid 46641614)
67. Grant SC, Kris MG, Houghton AN, Chapman PB. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus bacillus Calmette- Guérin. Clin. Cancer Res. 5(6), 1319-1323 (1999 (Pubitemid 29282934)
68. Giaccone G, Debruyne C, Felip E et al. Phase III study of adjuvant vaccination with BEC2/bacille Calmette-Guérin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva StudyJ. Clin. Oncol. 23(28), 6854-6864 (2005
69. Bottomley A, Debruyne C, Felip E et al. Symptom and quality of life results of an international randomised Phase III study of adjuvant vaccination with BEC2/BCG in responding patients with limited disease small-cell lung cancer. Eur. J. Cancer 44(15), 2178-2184 (2008
70. Shariat SF, Chade DC, Karakiewicz PI, Scherr DS, Dalbagni G. Update on intravesical agents for non-muscle-invasive bladder cancer. Immunotherapy 2(3), 381-392 (2010
71. Vural B, Chen LC, Saip P et al. Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters. Cancer 103(12), 2575-2583 (2005 (Pubitemid 40800537)
72. Livingston PO, Hood C, Krug LM et al. Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy. Cancer Immunol. Immunother. 54(10), 1018-1025 (2005 (Pubitemid 41187710)
73. Abraham DT, Low TH, Messina M et al. Medullary thyroid carcinoma: long-term outcomes of surgical treatment. Ann. Surg. Oncol. 18(1), 219-225 (2011
74. Marinoni I, Pellegata NS. p27kip1: a new multiple endocrine neoplasia gene? Neuroendocrinology 93(1), 19-28 (2011
75. Traugott A, Moley JF. Medullary thyroid cancer: medical management and follow-up. Curr. Treat. Options Oncol. 6(4), 339-346 (2005 (Pubitemid 41223387)
76. Kebebew E, Greenspan FS, Clark OH, Woeber KA, Grunwell J. Extent of disease and practice patterns for medullary thyroid cancer. J. Am. Coll. Surg. 200(6), 890-896 (2005 (Pubitemid 40744797)
77. Bachleitner-Hofmann T, Friedl J, Hassler M et al. Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma. Oncol. Rep. 21(6), 1585-1592 (2009
78. Papewalis C, Wuttke M, Jacobs B et al. Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma. Horm. Metab. Res. 40(2), 108-116 (2008 (Pubitemid 351363421)
79. Lien MH, Baldwin BT, Thareja SK, Fenske NA. Merkel cell carcinoma: clinical characteristics, markers, staging and treatment. J. Drugs Dermatol. 9(7), 779-784 (2010
80. Ramqvist T, Dalianis T. Lessons from immune responses and vaccines against murine polyomavirus infection and polyomavirus-induced tumours potentially useful for studies on human polyomaviruses. Anticancer Res. 30(2), 279-284 (2010
81. Tadmor T, Aviv A, Polliack A. Merkel cell carcinoma, chronic lymphocytic leukemia and other lymphoproliferative disorders: an old bond with possible new viral ties. Ann. Oncol. 22(2), 250-256 (2011
82. Pastrana DV, Tolstov YL, Becker JC, Moore PS, Chang Y, Buck CB. Quantitation of human seroresponsiveness to Merkel cell polyomavirus. PLoS Pathog. 5(9), e1000578 (2009
83. Paulson KG, Carter JJ, Johnson LG et al. Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. Cancer Res. 70(21), 8388-8397 (2010
84. Pastrana DV, Gambhira R, Buck CB et al. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 337(2), 365-372 (2005 (Pubitemid 40803480)
85. Rindi G, Inzani F, Solcia E. Pathology of gastrointestinal disorders. Endocrinol. Metab. Clin. North Am. 39(4), 713-727 (2010
86. Alvarez MC, Macias AA, Saurez MG, Fernandez ML, Lage DA. Bronchial carcinoid tumor treated with interferon and a new vaccine against NeuGcGM3 antigen expressed in malignant carcinoid cells. Cancer Biol. Ther. 6(6), 853-855 (2007 (Pubitemid 351574973)
87. Cheah PL, Looi LM. Biology and pathological associations of the human papillomaviruses: a review. Malays. J. Pathol. 20(1), 1-10 (1998
88. Joseph DA, Miller JW, Wu X et al. Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer 113(Suppl. 10), 2892-2900 (2008
89. Fendrich V, Waldmann J, Bartsch DK, Langer P. Surgical management of pancreatic endocrine tumors. Nat. Rev. Clin. Oncol. 6(7), 419-428 (2009
90. Hansel DE, House MG, Ashfaq R, Rahman A, Yeo CJ, Maitra A. MAGE1 is expressed by a subset of pancreatic endocrine neoplasms and associated lymph node and liver metastases. Int. J. Gastrointest. Cancer 33(2-3), 141-147 (2003 (Pubitemid 37553346)
91. Van Baren N, Bonnet MC, Dreno B et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J. Clin. Oncol. 23(35), 9008-9021 (2005 (Pubitemid 46211485)
92. Morris-Stiff G, Teli M, Jardine N, Puntis MC. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease. Hepatobiliary Pancreat. Dis. Int. 8(6), 620-626 (2009
93. Yuan J, Gnjatic S, Li H et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl Acad. Sci. USA 105(51), 20410-20415 (2008
94. Jacobs JF, Brasseur F, Hulsbergen-Van De Kaa CA et al. Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. Int. J. Cancer 120(1), 67-74 (2007 (Pubitemid 44901919)
95. Old LJ. Cancer vaccines: an overview. Cancer Immun. 8(Suppl. 1), 1 (2008
96. Frick JS, Grunebach F, Autenrieth IB. Immunomodulation by semi-mature dendritic cells: a novel role of Toll-like receptors and interleukin-6. Int. J. Med. Microbiol. 300(1), 19-24 (2010
97. Ilarregui JM, Rabinovich GA. Tolerogenic dendritic cells in the control of autoimmune neuroinflammation: an emerging role of protein-glycan interactions. Neuroimmunomodulation 17(3), 157-160 (2010
98. Weissman D, Ni H, Scales D et al. HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response. J. Immunol. 165(8), 4710-4717 (2000
99. Simon T, Fonteneau JF, Gregoire M. Dendritic cell preparation for immunotherapeutic interventions. Immunotherapy 1(2), 289-302 (2009
100. Mueller SN, Jones CM, Stock AT, Suter M, Heath WR, Carbone FR. CD4+ T cells can protect APC from CTL-mediated elimination. J. Immunol. 176(12), 7379-7384 (2006 (Pubitemid 43849039)
101. Ludewig B, Bonilla WV, Dumrese T, Odermatt B, Zinkernagel RM, Hengartner H. Perforin-independent regulation of dendritic cell homeostasis by CD8(+) T cells in vivo: implications for adaptive immunotherapy. Eur. J. Immunol. 31(6), 1772-1779 (2001 (Pubitemid 32547340)
102. Eroukhmanoff L, Oderup C, Ivars F. T-cell tolerance induced by repeated antigen stimulation: selective loss of FOXP3- conventional CD4 T cells and induction of CD4 T-cell anergy. Eur. J. Immunol. 39(4), 1078-1087 (2009
103. Badovinac VP, Messingham KA, Jabbari A, Haring JS, Harty JT. Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination. Nat. Med. 11(7), 748-756 (2005 (Pubitemid 41021207)
104. Pham NL, Pewe LL, Fleenor CJ et al. Exploiting cross-priming to generate protective CD8 T-cell immunity rapidly. Proc. Natl Acad. Sci. USA 107(27), 12198-12203 (2010
105. Wong P, Lara-Tejero M,Ploss A, Leiner I, Pamer EG. Rapiddevelopment of T cell memory. J. Immunol. 172(12), 7239-7245 (2004 (Pubitemid 38747582)
106. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 22(3), 659-661 (2008 (Pubitemid 351348146)
107. Butts CL, Sternberg EM. Neuroendocrine factors alter host defense by modulating immune function. Cell Immunol. 252(1-2), 7-15 (2008
108. Brubaker PL, Drucker DJ, Asa SL, Swallow C, Redston M, Greenberg GR. Prolonged gastrointestinal transit in a patient with a glucagon-like peptide (GLP)-1- and -2-producing neuroendocrine tumor. J. Clin. Endocrinol. Metab. 87(7), 3078-3083 (2002 (Pubitemid 34816348)
109. Skinner MM, Nass R, Lopes B, Laws ER, Thorner MO. Growth hormone secretagogue receptor expression in human pituitary tumors. J. Clin. Endocrinol. Metab. 83(12), 4314-4320 (1998 (Pubitemid 29100128)
110. Leontiou CA, Franchi G, Korbonits M. Ghrelin in neuroendocrine organs and tumours. Pituitary 10(3), 213-225 (2007 (Pubitemid 350055032)
111. Taylor AW. Neuroimmunomodulation and immune privilege: the role of neuropeptides in ocular immunosuppression. Neuroimmunomodulation 10(4), 189-198 (2002 (Pubitemid 36205295)
112. Garssen J, Buckley TL, Van Loveren H. A role for neuropeptides in UVB-induced systemic immunosuppression. Photochem. Photobiol. 68(2), 205-210 (1998 (Pubitemid 128472011)
113. Seiffert K, Granstein RD. Neuropeptides and neuroendocrine hormones in ultraviolet radiation-induced immunosuppression. Methods 28(1), 97-103 (2002).
114. Gonzalez-Rey E, Delgado M. Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis. Trends Mol. Med. 13(6), 241-251 (2007 (Pubitemid 46836872)
115. Taylor AW, Yee DG, Nishida T, Namba K. Neuropeptide regulation of immunity. The immunosuppressive activity of a-melanocyte-stimulating hormone (a-MSHAnn. NY Acad. Sci. 917, 239-247 (2000
116. Fabricius D, O'dorisio MS, Blackwell S, Jahrsdorfer B. Human plasmacytoid dendritic cell function: inhibition of IFN-a secretion and modulation of immune phenotype by vasoactive intestinal peptide. J. Immunol. 177(9), 5920-5927 (2006 (Pubitemid 44628805)
117. Moreno AM, Castilla-Guerra L, Martinez- Torres MC, Torres-Olivera F, Fernandez E, Galera-Davidson H. Expression of neuropeptides and other neuroendocrine markers in human phaeochromocytomas. Neuropeptides 33(2), 159-163 (1999 (Pubitemid 29254079)
118. Wai LE, Garcia JA, Martinez OM, Krams SM. Distinct roles for the NK cell-activating receptors in mediating interactions with dendritic cells and tumor cells. J. Immunol. 186(1), 222-229 (2011
119. Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin. Investig. Drugs 18(7), 1001-1011 (2009
120. Leon L, Areses MC, Anido U, Gomez A, Carballo AM. Poxviral-based prostate-specific antigen vaccine in prostate cancer. J. Clin. Oncol. 28(24), e416; author reply e417 (2010
121. Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC, Mccart JA. Intelligent design: combination therapy with oncolytic viruses. Mol. Ther. 18(2), 251-263 (2010
122. Bridle BW, Hanson S, Lichty BD. Combining oncolytic virotherapy and tumour vaccination. Cytokine Growth Factor Rev. 21(2-3), 143-148 (2010
123. Morton CL, Houghton PJ, Kolb EA et al. Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatr. Blood Cancer 55(2), 295-303 (2010